Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study

Amar Gajjar, Clinton F. Stewart, David W. Ellison, Sue Kaste, Larry E. Kun, Roger J. Packer, Stewart Goldman, Murali Chintagumpala, Dana Wallace, Naoko Takebe, James M. Boyett, Richard J. Gilbertson, Tom Curran

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. Experimental design: Initially, vismodegib was administered daily at 85 mg/m2 and escalated to 170 mg/m2. The study was then revised to investigate a flat-dosing schedule of 150 mg for patients with small body surface area (BSA, 0.67-1.32 m2) or 300 mg for those who were larger (BSA, 1.33-2.20 m 2). Pharmacokinetics were performed during the first course of therapy, and the right knees of all patients were imaged to monitor bone toxicity. Immunohistochemical analysis was done to identify patients with Sonic Hedgehog (SHH)-subtype medulloblastoma. Results: Thirteen eligible patients were enrolled in the initial study: 6 received 85 mg/m2 vismodegib, and 7 received 170 mg/m2. Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level. Three dose-limiting toxicities were observed, but no drug-related bone toxicity was documented. The median (range) vismodegib penetration in the cerebrospinal fluid (CSF) was 0.53 (0.26-0.78), when expressed as a ratio of the concentration of vismodegib in the CSF to that of the unbound drug in plasma. Antitumor activity was seen in 1 of 3 patients with SHH-subtype disease whose tumors were evaluable, and in none of the patients in the other subgroups. Conclusions: Vismodegib was well tolerated in children with recurrent or refractory medulloblastoma; only two dose-limiting toxicities were observed with flat dosing. The recommended phase II study dose is 150 or 300 mg, depending on the patient's BSA.

Original languageEnglish (US)
Pages (from-to)6305-6312
Number of pages8
JournalClinical Cancer Research
Volume19
Issue number22
DOIs
StatePublished - Nov 15 2013

Fingerprint

HhAntag691
Medulloblastoma
Brain Neoplasms
Pediatrics
Cerebrospinal Fluid
Pharmacokinetics
Bone and Bones
Body Surface Area
Pharmaceutical Preparations
Knee
Appointments and Schedules
Research Design

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I study of vismodegib in children with recurrent or refractory medulloblastoma : A pediatric brain tumor consortium study. / Gajjar, Amar; Stewart, Clinton F.; Ellison, David W.; Kaste, Sue; Kun, Larry E.; Packer, Roger J.; Goldman, Stewart; Chintagumpala, Murali; Wallace, Dana; Takebe, Naoko; Boyett, James M.; Gilbertson, Richard J.; Curran, Tom.

In: Clinical Cancer Research, Vol. 19, No. 22, 15.11.2013, p. 6305-6312.

Research output: Contribution to journalArticle

Gajjar, A, Stewart, CF, Ellison, DW, Kaste, S, Kun, LE, Packer, RJ, Goldman, S, Chintagumpala, M, Wallace, D, Takebe, N, Boyett, JM, Gilbertson, RJ & Curran, T 2013, 'Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study', Clinical Cancer Research, vol. 19, no. 22, pp. 6305-6312. https://doi.org/10.1158/1078-0432.CCR-13-1425
Gajjar, Amar ; Stewart, Clinton F. ; Ellison, David W. ; Kaste, Sue ; Kun, Larry E. ; Packer, Roger J. ; Goldman, Stewart ; Chintagumpala, Murali ; Wallace, Dana ; Takebe, Naoko ; Boyett, James M. ; Gilbertson, Richard J. ; Curran, Tom. / Phase I study of vismodegib in children with recurrent or refractory medulloblastoma : A pediatric brain tumor consortium study. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 22. pp. 6305-6312.
@article{fc0dbe708c074a77835fe7de6f43a536,
title = "Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study",
abstract = "Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. Experimental design: Initially, vismodegib was administered daily at 85 mg/m2 and escalated to 170 mg/m2. The study was then revised to investigate a flat-dosing schedule of 150 mg for patients with small body surface area (BSA, 0.67-1.32 m2) or 300 mg for those who were larger (BSA, 1.33-2.20 m 2). Pharmacokinetics were performed during the first course of therapy, and the right knees of all patients were imaged to monitor bone toxicity. Immunohistochemical analysis was done to identify patients with Sonic Hedgehog (SHH)-subtype medulloblastoma. Results: Thirteen eligible patients were enrolled in the initial study: 6 received 85 mg/m2 vismodegib, and 7 received 170 mg/m2. Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level. Three dose-limiting toxicities were observed, but no drug-related bone toxicity was documented. The median (range) vismodegib penetration in the cerebrospinal fluid (CSF) was 0.53 (0.26-0.78), when expressed as a ratio of the concentration of vismodegib in the CSF to that of the unbound drug in plasma. Antitumor activity was seen in 1 of 3 patients with SHH-subtype disease whose tumors were evaluable, and in none of the patients in the other subgroups. Conclusions: Vismodegib was well tolerated in children with recurrent or refractory medulloblastoma; only two dose-limiting toxicities were observed with flat dosing. The recommended phase II study dose is 150 or 300 mg, depending on the patient's BSA.",
author = "Amar Gajjar and Stewart, {Clinton F.} and Ellison, {David W.} and Sue Kaste and Kun, {Larry E.} and Packer, {Roger J.} and Stewart Goldman and Murali Chintagumpala and Dana Wallace and Naoko Takebe and Boyett, {James M.} and Gilbertson, {Richard J.} and Tom Curran",
year = "2013",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-13-1425",
language = "English (US)",
volume = "19",
pages = "6305--6312",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Phase I study of vismodegib in children with recurrent or refractory medulloblastoma

T2 - A pediatric brain tumor consortium study

AU - Gajjar, Amar

AU - Stewart, Clinton F.

AU - Ellison, David W.

AU - Kaste, Sue

AU - Kun, Larry E.

AU - Packer, Roger J.

AU - Goldman, Stewart

AU - Chintagumpala, Murali

AU - Wallace, Dana

AU - Takebe, Naoko

AU - Boyett, James M.

AU - Gilbertson, Richard J.

AU - Curran, Tom

PY - 2013/11/15

Y1 - 2013/11/15

N2 - Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. Experimental design: Initially, vismodegib was administered daily at 85 mg/m2 and escalated to 170 mg/m2. The study was then revised to investigate a flat-dosing schedule of 150 mg for patients with small body surface area (BSA, 0.67-1.32 m2) or 300 mg for those who were larger (BSA, 1.33-2.20 m 2). Pharmacokinetics were performed during the first course of therapy, and the right knees of all patients were imaged to monitor bone toxicity. Immunohistochemical analysis was done to identify patients with Sonic Hedgehog (SHH)-subtype medulloblastoma. Results: Thirteen eligible patients were enrolled in the initial study: 6 received 85 mg/m2 vismodegib, and 7 received 170 mg/m2. Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level. Three dose-limiting toxicities were observed, but no drug-related bone toxicity was documented. The median (range) vismodegib penetration in the cerebrospinal fluid (CSF) was 0.53 (0.26-0.78), when expressed as a ratio of the concentration of vismodegib in the CSF to that of the unbound drug in plasma. Antitumor activity was seen in 1 of 3 patients with SHH-subtype disease whose tumors were evaluable, and in none of the patients in the other subgroups. Conclusions: Vismodegib was well tolerated in children with recurrent or refractory medulloblastoma; only two dose-limiting toxicities were observed with flat dosing. The recommended phase II study dose is 150 or 300 mg, depending on the patient's BSA.

AB - Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. Experimental design: Initially, vismodegib was administered daily at 85 mg/m2 and escalated to 170 mg/m2. The study was then revised to investigate a flat-dosing schedule of 150 mg for patients with small body surface area (BSA, 0.67-1.32 m2) or 300 mg for those who were larger (BSA, 1.33-2.20 m 2). Pharmacokinetics were performed during the first course of therapy, and the right knees of all patients were imaged to monitor bone toxicity. Immunohistochemical analysis was done to identify patients with Sonic Hedgehog (SHH)-subtype medulloblastoma. Results: Thirteen eligible patients were enrolled in the initial study: 6 received 85 mg/m2 vismodegib, and 7 received 170 mg/m2. Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level. Three dose-limiting toxicities were observed, but no drug-related bone toxicity was documented. The median (range) vismodegib penetration in the cerebrospinal fluid (CSF) was 0.53 (0.26-0.78), when expressed as a ratio of the concentration of vismodegib in the CSF to that of the unbound drug in plasma. Antitumor activity was seen in 1 of 3 patients with SHH-subtype disease whose tumors were evaluable, and in none of the patients in the other subgroups. Conclusions: Vismodegib was well tolerated in children with recurrent or refractory medulloblastoma; only two dose-limiting toxicities were observed with flat dosing. The recommended phase II study dose is 150 or 300 mg, depending on the patient's BSA.

UR - http://www.scopus.com/inward/record.url?scp=84888082077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888082077&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-1425

DO - 10.1158/1078-0432.CCR-13-1425

M3 - Article

C2 - 24077351

AN - SCOPUS:84888082077

VL - 19

SP - 6305

EP - 6312

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -